Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
United Kingdom
Enrollment target
~26 participants
Started
March 2026
Primary completion
August 2026
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Josh Thorley, PhD
University of Nottingham